Vitamin D in HIV-Infected patients

Current HIV/AIDS Reports

Volumn 8, Issue 3, 2011, Pages 133-141

  Lake, Jordan E ^a   Adams, John S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

25(OH)2D.HIV.ART.Efavirenz.Tenofovir; Vitamin D.25(OH)D.1

Indexed keywords

1,25 DIHYDROXYERGOCALCIFEROL; 25 HYDROXYVITAMIN D; ALKALINE PHOSPHATASE; COLECALCIFEROL; CYTOCHROME P450; DARUNAVIR; EFAVIRENZ; ERGOCALCIFEROL; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INTERLEUKIN 12; INTERLEUKIN 2; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RILPIVIRINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; BODY MASS; BODY WEIGHT; BONE DENSITY; CALCIUM ABSORPTION; CD4 LYMPHOCYTE COUNT; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EXPOSURE; DRUG SAFETY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERPARATHYROIDISM; HYPERTENSION; IMMUNE RESPONSE; MACROPHAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PATIENT COMPLIANCE; PHOTOSYNTHESIS; PHYSICAL ACTIVITY; POSTMENOPAUSE; PRACTICE GUIDELINE; PREGNANCY; RACE DIFFERENCE; RADIATION EXPOSURE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RISK FACTOR; SECONDARY HYPERPARATHYROIDISM; SEX DIFFERENCE; SIDE EFFECT; SKIN PIGMENTATION; T LYMPHOCYTE ACTIVATION; TOBACCO DEPENDENCE; TREATMENT DURATION; TUBULAR DYSFUNCTION; ULTRAVIOLET B RADIATION; VIRUS LOAD; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN DEFICIENCY; VITAMIN METABOLISM; VITAMIN SUPPLEMENTATION;

ADULT; DIETARY SUPPLEMENTS; HIV; HIV INFECTIONS; HUMANS; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 80055027956     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-011-0082-8     Document Type: Article

References (99)

1. Adams JS, Hewison M. Update in vitamin D. J Clin Endocrinol Metab. 2010;95(2):471-478.
2. Melamed ML, Michos ED, Post W, Astor B. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med. 2008;168(15):1629-1637.
3. Ginde AA, Scragg R, Schwartz RS, Camargo Jr CA. Prospective study of serum 25-hydroxyvitamin D level, cardiovascular disease mortality, and all-cause mortality in older U.S. adults. J Am Geriatr Soc. 2009;57(9):1595-1603.
4. Lips P. Vitamin D physiology. Prog Biophys Mol Biol. 2006;92 (1):4-8. (Pubitemid 43831956)
5. Forouhi NG, Luan J, Cooper A, Boucher BJ, Wareham NJ. Baseline serum 25-hydroxy vitamin d is predictive of future glycemic status and insulin resistance: the Medical Research Council Ely Prospective Study 1990-2000. Diabetes. 2008;57 (10):2619-2625.
6. Scragg R, Sowers M, Bell C. Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the Third National Health and Nutrition Examination Survey. Diabetes Care. 2004;27(12):2813-2818. (Pubitemid 39565042)
7. Bischoff-Ferrari HA, Shao A, Dawson-Hughes B, Hathcock J, Giovannucci E, Willett WC. Benefit-risk assessment of vitamin D supplementation. Osteoporos Int. 2009.
8. Hiremath GS, Cettomai D, Baynes M, Ratchford JN, Newsome S, Harrison D, et al. Vitamin D status and effect of low-dose cholecalciferol and high-dose ergocalciferol supplementation in multiple sclerosis. Mult Scler. 2009;15(6):735-740.
9. Medicine Io. Dietary reference intakes for calcium and vitamin D. [Brief Report]. 2010 November 2010.
10. Villamor E. A potential role for vitamin D on HIV infection? Nutr Rev. 2006;64(5 Pt 1):226-33. (Pubitemid 43953286)
11. Haug C, Muller F, Aukrust P, Froland SS. Subnormal serum concentration of 1,25-vitamin D in human immunodeficiency virus infection: correlation with degree of immune deficiency and survival. J Infect Dis. 1994;169(4):889-893. (Pubitemid 24102128)
12. Holick MF. Vitamin D: a D-Lightful health perspective. Nutr Rev. 2008;66(10 Suppl 2):S182-S194.
13. & Beard JA, Bearden A, Striker R. Vitamin D and the anti-viral state. J Clin Virol. 2011;50(3):194-200.
14. Prosser DE, Jones G. Enzymes involved in the activation and inactivation of vitamin D. Trends Biochem Sci. 2004;29(12):664-673. (Pubitemid 39491265)
15. Peterlik M, Cross HS. Vitamin D and calcium deficits predispose for multiple chronic diseases. Eur J Clin Invest. 2005;35(5):290-304. (Pubitemid 40675603)
16. Mathieu C, Gysemans C, Giulietti A, Bouillon R. Vitamin D and diabetes. Diabetologia. 2005;48(7):1247-1257. (Pubitemid 41186086)
17. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357 (3):266-281.
18. Holick MF. High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc. 2006;81(3):353-373. (Pubitemid 43334631)
19. Rosen CJ. Clinical practice. Vitamin D insufficiency. N Engl J Med. 2011;364(3):248-254.
20. Nagpal S, Na S, Rathnachalam R. Noncalcemic actions of vitamin D receptor ligands. Endocr Rev. 2005;26(5):662-687. (Pubitemid 41127276)
21. Lemire JM, Archer DC, Beck L, Spiegelberg HL. Immunosuppressive actions of 1,25-dihydroxyvitamin D3: preferential inhibition of Th1 functions. J Nutr. 1995;125(6 SUPPL.):1704S-1708S.
22. Rausch-Fan X, Leutmezer F, Willheim M, Spittler A, Bohle B, Ebner C, et al. Regulation of cytokine production in human peripheral blood mononuclear cells and allergen-specific th cell clones by 1alpha,25-dihydroxyvitamin D3. Int Arch Allergy Immunol. 2002;128(1):33-41. (Pubitemid 34621664)
23. Girasole G, Wang JM, Pedrazzoni M, Pioli G, Balotta C, Passeri M, et al. Augmentation of monocyte chemotaxis by 1 alpha,25- dihydroxyvitamin D3. Stimulation of defective migration of AIDS patients. J Immunol. 1990;145(8):2459-2464.
24. Orikasa M, Kawase T, Suzuki A. Induction of macrophagic and granulocytic differentiation of murine bone marrow progenitor cells by 1,25-dihydroxyvitamin D3. Calcif Tissue Int. 1993;53 (3):193-200. (Pubitemid 23249397)
25. Schauber J, Dorschner RA, Coda AB, Buchau AS, Liu PT, Kiken D, et al. Injury enhances TLR2 function and antimicrobial peptide expression through a vitamin D-dependent mechanism. J Clin Invest. 2007;117(3):803-811. (Pubitemid 46348539)
26. Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science. 2006;311(5768):1770-1773.
27. Adams JS, Ren S, Liu PT, Chun RF, Lagishetty V, GombartAF, et al. Vitamin d-directed rheostatic regulation of monocyte antibacterial responses. J Immunol. 2009;182(7):4289-4295.
28. Bergman P, Walter-Jallow L, Broliden K, Agerberth B, Soderlund J. The antimicrobial peptide LL-37 inhibits HIV-1 replication. Curr HIV Res. 2007;5(4):410-415. (Pubitemid 47040482)
29. Steinstraesser L, Tippler B, Mertens J, Lamme E, Homann HH, Lehnhardt M, et al. Inhibition of early steps in the lentiviral replication cycle by cathelicidin host defense peptides. Retrovirology. 2005;2:2.
30. Hong P, Corcoran K, Modlin R, Lee B, Krutzik S. HIV-1 ssRNA triggers a vitamin D-dependent antiviral pathway in human monocytes. 15th Conference on Retroviruses and Opportunistic Infections Boston, Massachusetts. 2008 February 2008.
31. Conesa-Botella A, Mathieu C, Colebunders R, Moreno-Reyes R, van Etten E, Lynen L, et al. Is vitamin D deficiency involved in the immune reconstruction inflammatory syndrome. AIDS Res Ther. 2009;6(4):1-5.
32. Van Den Bout-Van Den Beukel CJ, Fievez L, Michels M, Sweep FC, Hermus AR, Bosch ME, et al. Vitamin D deficiency among HIV type 1-infected individuals in the Netherlands: effects of antiretroviral therapy. AIDS Res Hum Retroviruses. 2008;24 (11):1375-1382.
33. Garcia Aparicio AM, Munoz Fernandez S, Gonzalez J, Arribas JR, Pena JM, Vazquez JJ, et al. Abnormalities in the bone mineral metabolism in HIV-infected patients. Clin Rheumatol. 2006;25 (4):537-539. (Pubitemid 44137629)
34. Rodriguez M, Daniels B, Gunawardene S, Gunawardene S, Robbins GK. High frequency of vitamin D deficiency in ambulatory HIV-positive patients. AIDS Res Hum Retroviruses. 2009;25(1):9-14.
35. Wasserman P, Rubin DS. Highly prevelent vitamin D deficiency and insufficiency in an urban cohort of HIV-infected men under care. AIDS Patient Care STDS. 2010;24(4):223-227.
36. Bang UC, Shakar SA, Hitz MF, Jespersen MS, Andersen O, Nielsen SD, et al. Deficiency of 25-hydroxyvitamin D in male HIV-positive patients: a descriptive cross-sectional study. Scand J Infect Dis. 2010;42:306-310.
37. Ahmed S, Zinkiewicz P, Ninivaggi M, Verley J, Yasmin T, Khan I, Feleke G, et al. Prevalence of vitamin D deficiency in HIV population: an analysis of NHANES. Abstracts from the 18th International AIDS Conference Vienna, Austria. [Abstract]. 2010 July 2010.
38. Bischof MG, Heinze G, Vierhapper H. Vitamin D status and its relation to age and body mass index. Horm Res. 2006;66(5):211-215. (Pubitemid 44597718)
39. Parikh SJ, Edelman M, Uwaifo GI, Freedman RJ, Semega-Janneh M, Reynolds J, et al. The relationship between obesity and serum 1,25-dihydroxy vitamin D concentrations in healthy adults. J Clin Endocrinol Metab. 2004;89(3):1196-1199. (Pubitemid 38368412)
40. Dao CN, Patel P, Overton ET, Rhame F, Pals SL, Johnson C, et al. Low vitamin D among HIV-infected adults: prevalence of and risk factors for low vitamin D Levels in a cohort of HIV-infected adults and comparison to prevalence among adults in the US general population. Clin Infect Dis. 2011;52(3):396-405.
41. Conesa-Botella A, Florence E, Lynen L, Colebunders R, Menten J, Moreno-Reyes R. Decrease of vitamin D concentration in patients with HIV infection on a non nucleoside reverse transcriptase inhibitor-containing regimen. AIDS Res Ther. 2010;7(40):1-6.
42. Mehta S, Giovannucci EL, Mugusi FM, Spiegelman D, Aboud S, Hertzmark E, et al. Vitamin D status of HIV-infected women and its association with HIV disease progression, anemia, and mortality. PLoS One. 2010;5(1):1-7.
43. BorderiM,Vescini F, Cozzi-LepriA,Di CaroA, Shlacht I, CassolaG, et al. Prevalence of hypovitaminosis D among HIV+ patients enrolled in a large italian cohort. 17th conference on retroviruses and opportunistic infections San Francisco, California. [Abstract]. 2010 February 2010.
44. Adeyemi OM, Agniel D, French A, Weber K, Tien PC, Glesby M, et al. High rates of vitamin D deficiency among HIV-infected and at-risk women in the United States. Abstracts from the 18th International AIDS Conference Vienna, Austria. [Abstract]. 2010 July 21, 2010.
45. Kosmiski LA, Bacchetti P, Kotler DP, Heymsfield SB, Lewis CE, Shlipak MG, et al. Relationship of fat distribution with adipokines in human immunodeficiency virus infection. J Clin Endocrinol Metab. 2008;93(1):216-224.
46. Brown TT, Xu X, John M, Singh J, Kingsley LA, Palella FJ, et al. Fat distribution and longitudinal anthropometric changes in HIVinfected men with and without clinical evidence of lipodystrophy and HIV-uninfected controls: a substudy of the Multicenter AIDS Cohort Study. AIDS Res Ther. 2009;6:8.
47. Boodram B, Plankey MW, Cox C, Tien PC, Cohen MH, Anastos K, et al. Prevalence and correlates of elevated body mass index among HIV-positive and HIV-negative women in the Women's Interagency HIV Study. AIDS Patient Care STDS. 2009;23 (12):1009-1016.
48. Haug CJ, Aukrust P, Haug E, Morkrid L, Muller F, Froland SS. Severe deficiency of 1,25-dihydroxyvitamin D3 in human immunodeficiency virus infection: association with immunological hyperactivity and only minor changes in calcium homeostasis. J Clin Endocrinol Metab. 1998;83(11):3832-3838. (Pubitemid 28513558)
49. Hanevold CD, Yamaguchi DT, Jordan SC. Tumor necrosis factor alpha modulates parathyroid hormone action in UMR-106-01 osteoblastic cells. J Bone Miner Res. 1993;8(10):1191-1200. (Pubitemid 23308112)
50. Cozzolino M, Vidal M, Arcidiacono MV, Tebas P, Yarasheski KE, Dusso AS. HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D. AIDS. 2003;17(4):513-520. (Pubitemid 36293104)
51. Ellfolk M, Norlin M, Gyllensten K, Wikvall K. Regulation of human vitamin D(3) 25-hydroxylases in dermal fibroblasts and prostate cancer LNCaP cells. Mol Pharmacol. 2009;75(6):1392-1399.
52. Hariparsad N, Nallani SC, Sane RS, Buckley DJ, Buckley AR, Desai PB. Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital. J Clin Pharmacol. 2004;44(11):1273-1281. (Pubitemid 39391486)
53. Gyllensten K, Josephson F, Lidman K, Saaf M. Severe vitamin D deficiency diagnosed after introduction of antiretroviral therapy including efavirenz in a patient living at latitude 59 degrees N. AIDS. 2006;20(14):1906-1907. (Pubitemid 44358915)
54. Teichmann J, Stephan E, Lange U, Discher T, Friese G, Lohmeyer J, et al. Osteopenia in HIV-infected women prior to highly active antiretroviral therapy. J Infect. 2003;46(4):221-227. (Pubitemid 36758180)
55. de Luis DA, Bachiller P, Aller R, de Luis J, Izaola O, Terroba MC, et al. Relation among micronutrient intakes with CD4 count in HIV infected patients. Nutr Hosp. 2002;17(6):285-289. (Pubitemid 44616131)
56. Mueller NJ, Fux CA, Ledergerber B, Elzi L, Schmid P, Dang T, et al. High Prevalence of Severe Vitamin D Deficiency in Combined Antiretroviral Therapy-naive and successfully treated Swiss HIV patients. AIDS. 2010;24(8):112701134.
57. Crutchley R, Crutchley R Jr. Risk factors for vitamin D deficiency in HIV. Risk factors for vitamin D deficiency in HIV-1 infected adults in the South-Central United States Abstracts from the 18th International AIDS Conference Vienna, Austria. [Abstract]. 2010 July 21, 2010.
58. Gandhi V, Kim JH, Psevdos G Jr, Espinoza F, Park J, Sharp V. Evaluation of vitamin D levels in HIV-infected patients at the Center of Comprehensive Care, St Lukés Roosevelt Hospital Center, New York, USA. Abstracts from the 18th International AIDS Conference Vienna, Austria. [Abstract]. 2010 July 21, 2010.
59. Stein EM, Yin MT, McMahon DJ, Shu A, Zhang CA, Ferris DC, et al. Vitamin D deficiency in HIV-infected Postmenopausal Hispanic and African-American Women. Osteoporos Int. 2010;10:1-11.
60. Welz T, Childs K, Ibrahim F, Poulton M, Taylor CB, Moniz CF, et al. Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphatase. AIDS. 2010;24(12):1923-1928.
61. Allavena C. Delpierre C, Rey D, Cuzin L, Duvivier C, Viget N, et al. Effects of ARV on vitamin D concentration in HIV-infected patients: a large prospective cohort analysis. Abstracts from the 18th Conference on Retroviruses and Opportunistic Infections Boston, MA. [Abstract]. 2-11 February 27-March 2, 2011.
62. Ross A, Judd SE, Hileman C, Labbato D, Storer N, Tangpricha V, et al. Vitamin D is linked to carotid intima-media thickness and immune reconstitution in HIV-infected individuals. Antivir Ther. in press.
63. Mehta S, Spiegelman D, Magusi F, Giovanucci E, Msmanga G, Fawzi W. Vitamin D HIV-related complications and HIV disease progression in women in Tanzania. Program and abstracts of the 17th Conference on Retroviruses and Opportuistic Infections (San Francisco, CA). [Abstract]. 2010.
64. Childs K, Fishman S, Factor S, Dieterich D, Mullen M, Branch A. First Report of Dose/Response Data of HIV-infected Men Treated with Vitamin D3 SUPPL.ement. 17th Conference on Retroviruses and Opportunistic Infections San Francisco, California. [Abstract]. 2010 February 2010.
65. Havens P, Hazra R, Stephensen C, van LoanM, Rutledge B, Bethel J, et al. Vitamin D3 SUPPL.ementation decreases PTH in HIV-infected youth being treated with TDF-containing combination ART: a randomized, double-blind, placebo-controlled multicenter trial: Adolescent Trials Network Study 063. Abstracts from the 18th Conference on Retroviruses and Opportunistic Infections Boston, MA. [Abstract]. 2011 February 27-March 2, 2011.
66. Longenecker C, Hileman C, Carman C, Ross A, Tangpricha V, Seydafkan S, et al. Vitamin D SUPPL.ementation and endothelial function among vitamin D-deficient HIV-infected persons: a randomized placebo-controlled trial Abstracts from the 18th Conference on Retroviruses and Opportunistic Infections Boston, MA. [Abstract]. 2011 February 27-March 2, 2011.
67. Brown TT, McComsey GA. Association between initiation of antiretroviral therapy with efavirenz and decreases in 25- hydroxyvitamin D. Antivir Ther. 2010;15(3):425-429.
68. Fox J, Peters B, Prakash M, Arribas J, Hill A, Moecklinghoff C. Improvement in Vitamin D deficiency following antiretroviral regime change: results from the MONET trial. AIDS Res Hum Retroviruses. 2010;26(11):1-6.
69. Lattuada E, Lanzafame M, Zoppini G, Concia E, Vento S. No influence of nevirapine on Vitamin D deficiency in HIV-infected patients. AIDS Res Hum Retroviruses. 2009;25(8):849-850.
70. Wohl D, Doroana M, Orkin C, Pilotto JH, Sungkanuparph S, Yeni P, et al. Change in vitamin D levels smaller and risk of severe vitamin D deficiency lower among HIV-1-infected, treatmentnaive, adults receiving TMC278 compared with EFV: 48-week results from the phase III ECHO trial. Abstracts from the 18th Conference on Retroviruses and Opportunistic Infections Boston, MA. [Abstract]. 2011 February 27-March 2, 2011.
71. Portale AA, Halloran BP,Morris Jr RC. Physiologic regulation of the serum concentration of 1,25-dihydroxyvitamin D by phosphorus in normal men. J Clin Invest. 1989;83(5):1494-1499. (Pubitemid 19124102)
72. Kinai E, Hanabusa H. Renal tubular toxicity associated with tenofovir assessed using urine-beta 2 microglobulin, percentage of tubular reabsorption of phosphate and alkaline phosphatase levels. AIDS. 2005;19(17):2031-2033. (Pubitemid 41669029)
73. Labarga P, Barreiro P, Martin-Carbonero L, Rodriguez-Novoa S, Solera C, Medrano J, et al. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS. 2009;23(6):689-696.
74. Childs KE, Fishman SL, Constable C, Gutierrez JA, Wyatt CM, Dieterich DT, et al. Short communication: inadequate vitamin D exacerbates parathyroid hormone elevations in tenofovir users. AIDS Res Hum Retroviruses. 2010;26(8):855-859.
75. Pocaterra D, Ricci E, Carenzi L, Schiavini M, Meraviglia P, Minisci D, et al. Prevalence of hypovitaminosis D and factors associated in a sample of HIV patients. Abstracts from the 18th International AIDS Conference Vienna, Austria. 2010 July 21, 2010.
76. Gilead. Viread (tenofovir disoproxil fumarate) package insert. 2010.
77. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292(2):191-201. (Pubitemid 38917996)
78. Jacobson DL, Spiegelman D, Knox TK, Wilson IB. Evolution and predictors of change in total bone mineral density over time in HIV-infected men and women in the nutrition for healthy living study. J Acquir Immune Defic Syndr. 2008;49(3):298-308.
79. Fux C, Hasse B, Opravil M, Cavassini M, Calmy A, GurtnerdelaFuente V, et al. Bone turnover, and in particular osteoclast activity, is increased in patients with confirmed proximal renal tubulopathy within the Swiss HIV Cohort Study. 17th Conference on Retroviruses and Opportunistic Infections San Francisco, California. [Abstract]. 2010 February 2010.
80. Wirz S, Rubeli S, Christen A, Popp A, Largiadèr C, Mueller N, et al. Renal phosphate wasting and increased bone turnover in tenofovir-treated patients are not mediated by low 25(OH) Vitamin D or hyperparathyroidism. 17th Conference on Retroviruses and Opportunistic Infections San Francisco, California. [Abstract]. 2010 February 2010.
81. Rosenvinge MM, Gedela K, Copas AJ, Wilkinson A, Sheehy CA, Bano G, et al. Tenofovir-linked hyperparathyroidism is independently associated with the presence of vitamin D deficiency. J Acquir Immune Defic Syndr. 2010;54(5):496-9.
82. Labarga P, Barreiro P, Martin-Carbonero L, Alvarez E, Solera C, Pinilla J, et al. Prevalence and mechanisms of hyperparathyroidism in HIV+ patiens treated with TDF. Abstracts from the 18th Conference on Retroviruses and Opportunistic Infections Boston, MA. [Abstract]. 2011 Februrary 27-March 2, 2011.
83. Paul TV, Asha HS, Thomas N, Seshadri MS, Rupali P, Abraham OC, et al. Hypovitaminosis D and bone mineral density in HIV infected Indian men with or without antiretroviral therapy. Endocr Pract. 2010;16(4):547-553.
84. Marco Borderi FV, Cozzi-Lepri A, Di Caro A, Shlacht I, Cassola G, Pellizzer G, et al. Prevalence of hypovitaminosis D among HIV+ patients enrolled in a large Italian Cohort. 17th Conference on Retroviruses and Opportunistic Infections San Francisco, California. [Abstract]. 2010 February 2010.
85. Rachid T, Devitt E, Meyron I, Mandalia S,Waters L, Bower M, et al. No association of vitamin D levels with individual antiretroviral agents, duration of HIVinfection, alkaline phosphatase levels nor bone mineral density findings. Abstracts from the 18th International AIDS Conference Vienna, Austria. [Abstract]. 2010 July 21, 2010.
86. Campbell G, Stephen S. 1,25-dihydroxycholecalciferol triggers autophagy in human macrophages that inhibits productive HIV-1 Iinfection. 17th Conference on Retroviruses and Opportunistic Infections San Francisco, California. [Abstract]. 2010 February 2010.
87. Campbell G, Stephen S. Vitamin D3 triggers autophagy in human macrophages that inhibits productive HIV-1/TB co-infection. Abstracts from the 18th Conference on Retroviruses andOpportunistic Infections Boston, MA. [Abstract]. 2011 February 27-March 2, 2011.
88. Szep Z, Guaraldi G, Shah SS, Lo Re V 3rd, Ratcliffe SJ, Orlando G, et al. Vitamin D deficiency is associated with type 2 diabetes mellitus in HIV infection. AIDS 2011;25(00).
89. Guaraldi G, Zona S, Orlando G, Carli F, Ligabue G, Stentarelli C, et al. Vitamin D3 SUPPL.ementation decreases the risk of diabetes mellitus among patients with HIV infection. Abstracts from the 18th Conference on Retroviruses and Opportunistic Infections Boston, MA. [Abstract]. 2011 February 27-March 2, 2011.
90. Scragg R, Holdaway I, Singh V, Metcalf P, Baker J, Dryson E. Serum 25-hydroxyvitamin D3 levels decreased in impaired glucose tolerance and diabetes mellitus. Diabetes Res Clin Pract. 1995;27(3):181-188.
91. Maestro B, Campion J, Davila N, Calle C. Stimulation by 1,25- dihydroxyvitamin D3 of insulin receptor expression and insulin responsiveness for glucose transport in U-937 human promonocytic cells. Endocr J. 2000;47(4):383-391.
92. Norman AW, Frankel JB, Heldt AM, Grodsky GM. Vitamin D deficiency inhibits pancreatic secretion of insulin. Science. 1980;209(4458):823-825. (Pubitemid 10017495)
93. Cade C, Norman AW. Vitamin D3 improves impaired glucose tolerance and insulin secretion in the vitamin D-deficient rat in vivo. Endocrinology. 1986;119(1):84-90. (Pubitemid 16100711)
94. Chertow BS, Sivitz WI, Baranetsky NG, Clark SA, Waite A, Deluca HF. Cellular mechanisms of insulin release: the effects of vitamin D deficiency and repletion on rat insulin secretion. Endocrinology. 1983;113(4):1511-1518. (Pubitemid 13009167)
95. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 2006;20(17):2165-2174. (Pubitemid 44684707)
96. Yin MT, Lu D, Cremers S, Tien PC, Cohen MH, Shi Q, et al. Short-term bone loss in HIV-infected premenopausal women. J Acquir Immune Defic Syndr. 2010;53(2):202-208.
97. Shahar E, HassounG,KedemE, Pollack S. Low vitamin Dlevels and bone density changes in young HIV+ Israeli women Abstracts from the 18th Conference on Retroviruses and Opportunistic Infections Boston, MA. [Abstract]. 2011 February 27-March 2, 2011.
98. Choi AI, Lo JC, Mulligan K, Schnell A, Kalapus SC, Li Y, et al. Association of vitamin D insufficiency with carotid intima-media thickness in HIV-infected persons. Clin Infect Dis. 2011;52 (7):941-944.
99. Hanley DA, Cranney A, Jones G, Whiting SJ, Leslie WD, Cole DE, et al. Vitamin D in adult health and disease: a review and guideline statement from Osteoporosis Canada. CMAJ. 2010;182 (12):E610-E618.